|
News FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl
The U.S. Food and Drug Administration (FDA) is informing the public of new restrictions to the prescribing and use of rosiglitazone-containing medicines. |
|
News GSK revises US Avandia label to include new restrictions on use
GlaxoSmithKline (GSK) announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia, Avandamet and Avandaryl) to include additional safety information and restrictions on the use of these medicines. |
|
News European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim
Anti-diabetes medication to be taken off the market |
|
News CHMP meets to discuss Avandia and Pandemrix
The Committee for Medicinal Products for Human Use (CHMP) met on Wednesday 8 September to discuss the ongoing benefit-risk review of the rosiglitazone-containing medicines Avandia, Avandamet and Avaglim. |
|
News CHMP meeting on 8 September 2010 to discuss Avandia and Pandemrix
The Committee for Medicinal Products for Human Use (CHMP) is meeting on Wednesday 8 September to discuss the ongoing benefit-risk review of the rosiglitazone-containing medicines Avandia, Avandamet and Avaglim. |
|
News European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim
Doctors reminded to follow current restrictions for rosiglitazone-containing anti-diabetes medicines until further notice |
|
Leaflet Drug Metformin and Rosiglitazone (Oral Route)
Description: Metformin and rosiglitazone combination is used to treat high blood sugar levels that are caused by a type of diabetes mellitus or sugar diabetes called type 2 diabetes. |
|
Leaflet Drug Avandamet
Description: Metformin and rosiglitazone combination is used to treat high blood sugar levels that are caused by a type of diabetes mellitus or sugar diabetes called type 2 diabetes. |